Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women
- PMID: 17202311
- DOI: 10.1158/1078-0432.CCR-06-0267
Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women
Abstract
Purpose: Somatic mutations of PIK3CA, which encodes the p110alpha catalytic subunit of phosphatidylinositol 3-kinase, have recently been shown to play an important role in the pathogenesis and progression of human breast cancers. In this study, the frequency of PIK3CA mutations and their relationship with clinicopathologic and biological variables were investigated in Japanese breast cancers.
Experimental design: Mutational analysis of PIK3CA was done in 188 primary breast cancers of Japanese women. Relationship of these mutations with various clinicopathologic variables [histologic type, tumor size, histologic grade, lymph node status, estrogen receptor (ER)-alpha and progesterone receptor status, and prognosis], biological variables [phospho-AKT (pAKT) and HER2 expression determined by immunohistochemistry], and p53 mutation status was studied.
Results: Missense mutations of PIK3CA were found in 44 of 158 invasive ductal carcinomas, 4 of 10 invasive lobular carcinomas, 1 of 4 mucinous carcinomas, 2 of 2 squamous carcinomas, and 2 of 2 apocrine carcinomas, but no mutation was found in 12 noninvasive ductal carcinomas. PIK3CA-mutated tumors were found to be more likely to be ER-alpha positive (P < 0.05) and pAKT positive (P < 0.05). There was no significant association between PIK3CA mutations and p53 mutation status. PIK3CA mutations were significantly (P < 0.05) associated with a favorable prognosis, and multivariate analysis showed that PIK3CA mutation status was a significant (P < 0.05) prognostic factor independent of the other conventional prognostic factors.
Conclusions: The frequency of PIK3CA mutations in Japanese breast cancers is similar to that of Caucasian breast cancers. Association of PIK3CA mutations with positive pAKT and positive ER-alpha suggests that PIK3CA mutations might exert their effects through activation of the phosphatidylinositol 3-kinase/AKT/ER-alpha pathway. PIK3CA mutations seem to have a potential to be used as an indicator of favorable prognosis.
Similar articles
-
PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.Exp Mol Pathol. 2010 Feb;88(1):150-5. doi: 10.1016/j.yexmp.2009.09.016. Epub 2009 Oct 8. Exp Mol Pathol. 2010. PMID: 19818761
-
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.J Pathol. 2006 Feb;208(3):350-5. doi: 10.1002/path.1908. J Pathol. 2006. PMID: 16353168
-
PIK3CA mutations in breast cancer are associated with poor outcome.Breast Cancer Res Treat. 2006 Mar;96(1):91-5. doi: 10.1007/s10549-005-9048-0. Epub 2005 Nov 30. Breast Cancer Res Treat. 2006. PMID: 16317585
-
Oncogenic PI3K deregulates transcription and translation.Nat Rev Cancer. 2005 Dec;5(12):921-9. doi: 10.1038/nrc1753. Nat Rev Cancer. 2005. PMID: 16341083 Review.
-
The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer.Chin J Cancer. 2012 Jul;31(7):327-34. doi: 10.5732/cjc.012.10032. Epub 2012 May 24. Chin J Cancer. 2012. PMID: 22640628 Free PMC article. Review.
Cited by
-
Characterizing the Tumor Microenvironment and Its Prognostic Impact in Breast Cancer.Cells. 2024 Sep 10;13(18):1518. doi: 10.3390/cells13181518. Cells. 2024. PMID: 39329702 Free PMC article.
-
PIK3CA mutations in breast cancer: A Tunisian series.PLoS One. 2023 May 17;18(5):e0285413. doi: 10.1371/journal.pone.0285413. eCollection 2023. PLoS One. 2023. PMID: 37195967 Free PMC article.
-
Predicting prognosis and clinical features of the tumor microenvironment based on ferroptosis score in patients with breast cancer.Sci Rep. 2022 Jun 23;12(1):10611. doi: 10.1038/s41598-022-14964-7. Sci Rep. 2022. PMID: 35739315 Free PMC article.
-
PIK3CA Mutation as Potential Poor Prognostic Marker in Asian Female Breast Cancer Patients Who Received Adjuvant Chemotherapy.Curr Oncol. 2022 Apr 19;29(5):2895-2908. doi: 10.3390/curroncol29050236. Curr Oncol. 2022. PMID: 35621626 Free PMC article.
-
The Role of Progesterone Receptors in Breast Cancer.Drug Des Devel Ther. 2022 Jan 26;16:305-314. doi: 10.2147/DDDT.S336643. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 35115765 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous